<DOC>
	<DOCNO>NCT00253110</DOCNO>
	<brief_summary>The purpose study compare time relapse patient schizophrenia schizoaffective disorder receive risperidone haloperidol ( antipsychotic medication ) least 1 year .</brief_summary>
	<brief_title>A Comparison Risperidone With Haloperidol Patients With Schizophrenia Schizoaffective Disorder</brief_title>
	<detailed_description>Schizophrenia severe mental illness cause change person 's perception , thought , behaviour . In schizophrenic , common symptom positive symptom ( delusion hallucination ) , negative symptom ( avoid social situation , lack feeling expression ) , disorganize symptom ( confusion think speech ) . Schizoaffective disorder different schizophrenia , although may misdiagnosed illness . Schizoaffective disorder mental illness distinguish combination think disorder ( abnormal thinking psychotic symptom hallucination delusion ) mood disorder ( clinical depression manic component ) . Manic symptom include , limited overinflated self esteem , increase physical agitation , excessively poor judgment , easily distract , increased irritability energy level . This randomized , double-blind , parallel-group , control study comparing time relapse incidence relapse patient schizophrenia schizoaffective disorder treat risperidone haloperidol . The long-term safety effectiveness risperidone haloperidol also compare . The study compose two phase : 1-week baseline period double-blind treatment period . During baseline period , dose risperidone haloperidol gradually increase 4 mg/day risperidone 10 mg/day haloperidol . During first 4 week double-blind treatment , dosage adjustment make range 2 - 8 mg/day risperidone 5 - 20 mg/day haloperidol , base clinical evaluation patient . The double-blind treatment continue dose last patient enter study completes 1 year treatment maximum 112 week . The primary measure effectiveness time relapse , define use six criterion indicate patient 's illness long control ( example , psychiatric hospitalization ) . Additional efficacy test conduct include Positive Negative Syndrome Scale Schizophrenia ( PANSS ) , rating scale measure symptoms schizophrenia ; Clinical Global Impressions ( CGI ) , rating system use evaluate overall severity clinical change patient various disease affect brain ; Quality Life Interview ( QOLI ) , global measure satisfaction life . Safety evaluation include incidence adverse event , result clinical laboratory test ( hematology , biochemistry , urinalysis ) , measurement vital sign body weight , physical examination electrocardiogram ( ECG ) finding , Extrapyramidal Symptoms Rating Scale ( ESRS ) , scale use measure effect antipsychotic medication motor function patient . The study hypothesis risperidone effective delaying relapse haloperidol patient schizophrenia schizoaffective disorder . Risperidone tablet , take orally , start 1 mg/day ; increase 4 mg/day ( Week 1 ) . Haloperidol tablet , take orally , start 2 mg/day ; increase 10 mg/day ( Week 1 ) . After Week 1 , dosage may adjust ( 2 - 8 mg/day risperidone ; 5 - 20 mg/day haloperidol ) . Treatment duration &gt; =52 week .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Diagnosis schizophrenia schizoaffective disorder , accord Diagnostic Statistical Manual Mental Diseases , 4th edition ( DSMIV ) criterion document 1year history schizophrenia schizoaffective disorder since first drug treatment psychotic symptom history within previous 24 month discharge inpatient psychiatric unit , partial hospitalization , complete crisis management intervention , stay hospital emergency room hold area least 12 hour must receive stable dose antipsychotic medication 30 day study entry investigator 's judgment , must able discontinue current antipsychotic medication . Patients clinically significant neurological disorder , exception DSMIV define movement disorder cause drug patient another current DSMIV Axis I diagnosis ( except nicotine caffeine dependence ) history current diagnosis gastrointestinal , liver , kidney disease condition might interfere study drug absorb , process , excrete body pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Schizophrenia , Psychotic Disorders</keyword>
	<keyword>Haloperidol</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Schizoaffective disorder</keyword>
</DOC>